Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1498–1502. doi: 10.1038/bjc.1996.283

Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.

J F Tsai 1, J E Jeng 1, M S Ho 1, W Y Chang 1, M Y Hsieh 1, Z Y Lin 1, J H Tsai 1
PMCID: PMC2074539  PMID: 8664119

Abstract

To assess the role of hepatitis B e antigen (HBeAg) and its interaction with hepatitis B surface antigen (HBsAg) on the development of hepatocellular carcinoma (HCC), this case-control study included 361 age- and sex-matched pairs of patients with histologically proven HCC and healthy control subjects. HBsAg, HBeAg and antibody to HBeAg (anti-HBe) were detected by radioimmunoassay. Antibodies to hepatitis C virus (anti-HCV) were detected by second-generation enzyme immunoassay. The prevalences of HBeAg (20.2%), HBsAg (80.3%) and anti-HCV (29.5%) in cases were higher than in controls (1.9%, 20.7%, and 2.7% respectively; each P < 0.0001). Using patients negative for HBsAg, HBeAg and anti-HBe as a referent group, univariate analysis indicated that HBsAg alone or HBsAg and HBeAg were risk factors for HCC (P for trend < 0.0001). Calculation of incremental odds ratio indicated that there was additive interaction between HBsAg and HBeAg. Multivariate analysis indicated that HCC development was strongly associated with the presence of HBeAg (odds ratio, 8.1; 95% confidence interval, 2.4-27.1), HBsAg (odds ratio, 68.4; 95% confidence interval, 20.5-227.8) and anti-HCV (odds ratio, 59.3; 95% confidence interval, 13.6-258.4). In conclusion, HBsAg, HBeAg and anti-HCV are independent risk factors for HCC. There is additive and independent effect modification between HBsAg and HBeAg on the development of HCC.

Full text

PDF
1498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chen C. J., Liang K. Y., Chang A. S., Chang Y. C., Lu S. N., Liaw Y. F., Chang W. Y., Sheen M. C., Lin T. M. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991 Mar;13(3):398–406. [PubMed] [Google Scholar]
  2. Chen C. J., Tseng S. F., Lu C. F., Lin H. C., You S. L., Chen C. S., Hwang S. J., Hsieh S. F., Hsu S. T. Current seroepidemiology of hepatitis D virus infection among hepatitis B surface antigen carriers of general and high-risk populations in Taiwan. J Med Virol. 1992 Oct;38(2):97–101. doi: 10.1002/jmv.1890380205. [DOI] [PubMed] [Google Scholar]
  3. Chen D. S., Lai M. Y., Sung J. L. Delta agent infection in patients with chronic liver diseases and hepatocellular carcinoma--an infrequent finding in Taiwan. Hepatology. 1984 May-Jun;4(3):502–503. doi: 10.1002/hep.1840040324. [DOI] [PubMed] [Google Scholar]
  4. Chen D. S. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):470–475. doi: 10.1111/j.1440-1746.1993.tb01551.x. [DOI] [PubMed] [Google Scholar]
  5. Galloway D. A., McDougall J. K. The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature. 1983 Mar 3;302(5903):21–24. doi: 10.1038/302021a0. [DOI] [PubMed] [Google Scholar]
  6. Jeng J. E., Tsai J. F. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol. 1991 May;34(1):74–77. doi: 10.1002/jmv.1890340113. [DOI] [PubMed] [Google Scholar]
  7. Kew M. C., Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984 May;4(2):136–146. doi: 10.1055/s-2008-1040653. [DOI] [PubMed] [Google Scholar]
  8. Leung N. W., Tam J. S., Lau G. T., Leung T. W., Lau W. Y., Li A. K. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer. 1994 Feb 15;73(4):1143–1148. doi: 10.1002/1097-0142(19940215)73:4<1143::aid-cncr2820730404>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Lin T. M., Chen C. J., Lu S. N., Chang A. S., Chang Y. C., Hsu S. T., Liu J. Y., Liaw Y. F., Chang W. Y. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res. 1991 Nov-Dec;11(6):2063–2065. [PubMed] [Google Scholar]
  10. Popper H., Thung S. N., McMahon B. J., Lanier A. P., Hawkins I., Alberts S. R. Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. Arch Pathol Lab Med. 1988 May;112(5):498–504. [PubMed] [Google Scholar]
  11. Raimondo G., Campo S., Smedile V., Rodinò G., Sardo M. A., Brancatelli S., Villari D., Pernice M., Longo G., Squadrito G. Hepatitis B virus variant, with a deletion in the preS2 and two translational stop codons in the precore regions, in a patient with hepatocellular carcinoma. J Hepatol. 1991;13 (Suppl 4):S74–S77. doi: 10.1016/0168-8278(91)90029-b. [DOI] [PubMed] [Google Scholar]
  12. Schirmacher P., Rogler C. E., Dienes H. P. Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63(2):71–89. doi: 10.1007/BF02899246. [DOI] [PubMed] [Google Scholar]
  13. Thomas H. C., Carman W. F. Envelope and precore/core variants of hepatitis B virus. Gastroenterol Clin North Am. 1994 Sep;23(3):499–514. [PubMed] [Google Scholar]
  14. Tsai J. F., Chang W. Y., Jeng J. E., Ho M. S., Lin Z. Y., Tsai J. H. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer. 1994 Jun;69(6):1157–1159. doi: 10.1038/bjc.1994.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tsai J. F., Chang W. Y., Jeng J. E., Ho M. S., Lin Z. Y., Tsai J. H. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver. 1994 Apr;14(2):98–102. doi: 10.1111/j.1600-0676.1994.tb00055.x. [DOI] [PubMed] [Google Scholar]
  16. Tsai J. F., Chang W. Y., Jeng J. E., Ho M. S., Wang L. Y., Hsieh M. Y., Chen S. C., Chuang W. L., Lin Z. Y., Tsai J. H. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol. 1993 Dec;41(4):296–300. doi: 10.1002/jmv.1890410407. [DOI] [PubMed] [Google Scholar]
  17. Tsai J. F., Jeng J. E., Chang W. Y., Ho M. S., Lin Z. Y., Tsai J. H. Circulating immune complexes in chronic hepatitis C. J Med Virol. 1995 May;46(1):12–17. doi: 10.1002/jmv.1890460104. [DOI] [PubMed] [Google Scholar]
  18. Tsai J. F., Jeng J. E., Chang W. Y., Ho M. S., Lin Z. Y., Tsai J. H. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine (Baltimore) 1995 May;74(3):136–143. doi: 10.1097/00005792-199505000-00003. [DOI] [PubMed] [Google Scholar]
  19. Tsai J. F., Jeng J. E., Ho M. S., Chang W. Y., Lin Z. Y., Tsai J. H. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. Br J Cancer. 1995 Aug;72(2):442–446. doi: 10.1038/bjc.1995.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tsai J. F., Jeng J. E., Ho M. S., Chang W. Y., Lin Z. Y., Tsai J. H. Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case-control study. Int J Cancer. 1994 Mar 1;56(5):619–621. doi: 10.1002/ijc.2910560502. [DOI] [PubMed] [Google Scholar]
  21. Tsai J. F., Margolis H. S., Fields H. A., Chang W. Y., Tsai J. H. Hepatitis delta virus superinfection among patients with chronic hepatitis B in southern Taiwan. Scand J Infect Dis. 1990;22(4):403–405. doi: 10.3109/00365549009027070. [DOI] [PubMed] [Google Scholar]
  22. Tsai J. F., Margolis H. S., Jeng J. E., Ho M. S., Chang W. Y., Lin Z. Y., Tsai J. H. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol. 1995 Apr;75(1):39–44. doi: 10.1006/clin.1995.1050. [DOI] [PubMed] [Google Scholar]
  23. Tsai J. F., Tsai J. H., Chang W. Y. Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Gastroenterol Jpn. 1990 Jun;25(3):388–393. doi: 10.1007/BF02779456. [DOI] [PubMed] [Google Scholar]
  24. Tsai J. F., Tsai J. H., Chang W. Y., Ton T. C. Elevation of circulating immune complexes and its relationship to alpha-fetoprotein levels in patients with hepatitis B surface antigen-positive hepatocellular carcinoma. Cancer Invest. 1991;9(2):137–143. doi: 10.3109/07357909109044224. [DOI] [PubMed] [Google Scholar]
  25. Zaman S., Khan M., Alam K., Williams R. Primary hepatocellular carcinoma and viral hepatitis B and C infection in Bangladeshi subjects. J Trop Med Hyg. 1995 Feb;98(1):64–68. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES